Facial Atopic Dermatitis and Atopic Keratoconjunctivitis (AKC) - Clinical Study [US,CA] (Email,Social,Banner,Native,Push,SEO,Search,Brand Bidding) - CPL
Offer Details: |
Offer Name: |
Facial Atopic Dermatitis and Atopic Keratoconjunctivitis (AKC) - Clinical Study [US,CA] (Email,Social,Banner,Native,Push,SEO,Search,Brand Bidding) - CPL
|
Payout: |
$125.00 /
cpa
|
Preview: |
Preview Landing Page
|
Categories: | Health |
Network: |
SmartAdv
|
Last Updated: | Nov 13, 2024 |
Countries: |
US / CA
|
---|
Run Offer
Conversion Point: Valid Form Fill
Ages: 18+
Gender: Any
Compensation: Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated up to $1575 for 7 visits or $2475 for 11 visits for time and travel.
GEO: US Only
Traffic Allowed: Email, Social, Banner, Native, Push, SEO, Search, Brand Bidding
No Incent
No Co-Reg
No Survey
No SMS
No Adult
Send ad creatives and LP to AM for approval
Forbidden traffic types/false Advertisements Will NOT Be Paid For
Fake/false celebrity ads/endorsements are strictly prohibited
Qualifications:
- Must currently have an active eczema rash on your face
- Eczema rash must affect your eyes or eyelids
- if eligible to participate, you will be asked to discontinue wearing contact lenses for the duration of the study
Study Description:
The purpose of this clinical study is to see how effective an investigational medication is at helping to treat a condition known as atopic keratoconjunctivitis, or AKC. AKC presents as red, itchy eyes and eye lids and is commonly seen in patients with facial eczema that affects the eyes and/or eye lids. The study medication is currently FDA approved to treat several inflammatory conditions and is being explored as a new therapy option for patients with AKC. You will be asked to attend a screening visit to determine if you are eligible to enroll in the study. If enrolled, you will receive either the injectable medication being tested in this study or a placebo to be administered every 7 days for a total of 16 weeks of treatment. Your total participation will last approximately 4 months and you will be asked to attend 7 doctor’s visits. After 4 months, participants will be offered the chance to join an optional open-label period where they will receive the study medication for up to an additional 16 weeks of treatment. Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated up to $1575 for 7 visits or $2475 for 11 visits for time and travel. During study visits, you will complete various procedures and tests that will include visual tests, eye exams, vitals, and physical exams. The doctor’s office conducting the study will be able to provide you with more information about the study requirements.